Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 501 to 550 of 1866 results for do not do

  1. Cardiovascular disease prevention: primary prevention with lifestyle changes (IND228)

    This indicator covers the percentage of patients with a cardiovascular disease risk assessment score of 10% or more identified in the preceding 12 months who are offered advice and support for smoking cessation, safe alcohol consumption, healthy diet and exercise within 3 months of the score being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM210

  2. Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)

    Evidence-based recommendations on diroximel fumarate (Vumerity) for active relapsing–remitting multiple sclerosis in adults.

  3. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

    Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.

  4. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for vaginal vault prolapse

    years later, and it's not known for certain what all of them might be. If they do develop they might not trouble you very much, or they...

  5. Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

    Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.

  6. Antenatal and postnatal mental health (QS115)

    This quality standard covers recognising, assessing and treating mental health problems in women planning, during or after pregnancy (up to a year after childbirth). It also covers the organisation of mental health services for women during and after pregnancy. It describes high-quality care in priority areas for improvement.

  7. Rheumatoid arthritis: cardiovascular risk assessment (IND108)

    This indicator covers the percentage of patients with rheumatoid arthritis (RA) aged 30 to 84 years who have had a cardiovascular risk assessment using a cardiovascular disease (CVD) risk assessment tool adjusted for RA in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM56

  8. Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)

    This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance.

  9. ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment (HTG664)

    Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.

  10. Transcutaneous electrical neuromuscular stimulation for urinary incontinence (HTG636)

    Evidence-based recommendations on transcutaneous electrical neuromuscular stimulation for urinary incontinence in adults. This involves stimulating nerves and muscles in the pelvic floor to strengthen the muscles and reduce urine leaks.

  11. High-intensity focused ultrasound for symptomatic breast fibroadenoma (HTG449)

    Evidence-based recommendations on high-intensity focused ultrasound for symptomatic breast fibroadenoma in adults. This involves using high-frequency sound waves to heat up the tissues in the lump.

  12. NICE Health Technology Assessment training programme

    We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.

  13. NICE Health Technology Assessment training programme

    We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.

  14. Drug allergy: diagnosis and management (CG183)

    This guideline covers diagnosing and managing drug allergy in all age groups. It aims to make it easier for professionals to tell when someone is having an allergic reaction, by specifying the key signs and patterns to look out for. It also makes recommendations on improving people’s understanding of their drug allergies, and ensuring these are recorded properly in their medical records.

  15. Cerebral palsy in children and young people (QS162)

    This quality standard covers diagnosing, assessing and managing cerebral palsy in children and young people under 25. It describes high-quality care in priority areas for improvement.

  16. Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

    Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.

  17. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

    Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

  18. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST22)

    Evidence-based recommendations on ataluren (Translarna) for Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people 2 years and over who can walk.

  19. Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)

    Evidence-based recommendations on cetuximab (Erbitux) for treating locally advanced squamous cell cancer of the head and neck in adults.

  20. Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)

    Evidence-based recommendations on guselkumab (Tremfya) for previously treated moderately to severely active Crohn's disease.

  21. Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (HTG391)

    Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.

  22. Diabetes: did not attend retinal screening (IND68)

    This indicator covers the proportion of eligible people with diabetes who have not attended for diabetic eye screening in the previous 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG87

  23. NICE content assurance service

    NICE content assurance service

  24. Life sciences: how to get your product to market

    NICE Advice works closely with our system partners and industry to drive innovation into the hands of health and care professionals, to enable best practice.

  25. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  26. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  27. Mental health of adults in contact with the criminal justice system (QS163)

    This quality standard covers recognising, assessing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system (this includes police contact, court and prison custody, street triage, liaison and diversion services, and probation services). It describes high-quality care in priority areas for improvement.

  28. Dementia (QS184)

    This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.

  29. Hypothermia: prevention and management in adults having surgery (CG65)

    This guideline covers preventing and managing inadvertent hypothermia in people aged 18 and over having surgery. It offers advice on assessing patients’ risk of hypothermia, measuring and monitoring temperature, and devices for keeping patients warm before, during and after surgery.

  30. Stage 4: treatment, assessment and monitoring

    In virtual wards, people can receive virtual and technology-assisted treatment, assessment, and monitoring.

  31. Gynaecological conditions: rates of hysterectomy (heavy menstrual bleeding) (IND58)

    This indicator covers rates of hysterectomy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG77

  32. Asthma: objective tests (IND272)

    This indicator covers the percentage of patients with a new diagnosis of asthma on or after (start date) with a record of an objective test between 3 months before or 3 months after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  33. Heart failure: referral for cardiac rehabilitation (IND102)

    This indicator covers the percentage of patients with heart failure diagnosed within the preceding 15 months with a record of an offer of referral for an exercise-based rehabilitation programme. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM48

  34. Lateral elbow resurfacing for arthritis (HTG591)

    Evidence-based recommendations on lateral elbow resurfacing for arthritis. This involves inserting an implant into the 2 bones that form the joint at the outer part of the elbow, under general anaesthetic.

  35. Miniature lens system implantation for advanced age-related macular degeneration (HTG418)

    Evidence-based recommendations on miniature lens system implantation for advanced age-related macular degeneration. This involves implanting an artificial lens system into 1 eye only.

  36. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1071)

    Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults.

  37. Caval valve implantation for tricuspid regurgitation (HTG726)

    Evidence-based recommendations on caval valve implantation for tricuspid regurgitation in adults. This involves implanting valves into 1 or both caval veins without disturbing the tricuspid valve.

  38. Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease (HTG689)

    Evidence-based recommendations on aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease in adults. This involves replacing the diseased part of the valve with some of the person’s own pericardium.

  39. Single-step scaffold insertion for repairing symptomatic chondral knee defects (HTG728)

    Evidence-based recommendations on single-step scaffold insertion for repairing symptomatic chondral knee defects. This involves inserting a scaffold into the damaged area of the knee to support regrowth and repair of the cartilage.

  40. HTA Lab projects

    the environment. We're hoping to find a proportionate and pragmatic way to do this, bearing in mind that data and methods in this can...

  41. Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)

    Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.

  42. Hepatitis B and C testing: people at risk of infection (PH43)

    This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.

  43. Meetings in public

    Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.

  44. Meetings in public

    Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.

  45. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at moderately increased risk

    you may be offered regular scans to check for breast cancer. Most women who do develop breast cancer can be successfully treated. Your...

  46. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    you may be offered regular scans to check for breast cancer. Most women who do develop breast cancer can be successfully treated. Your...

  47. Rehabilitation after traumatic injury (NG211)

    This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.

  48. Excess winter deaths and illness and the health risks associated with cold homes (NG6)

    This guideline covers reducing the health risks (including preventable deaths) associated with living in a cold home. It aims to improve the health and wellbeing of people vulnerable to the cold. Improving the temperature in homes, by improving energy efficiency, may also help reduce unnecessary fuel consumption.

  49. Cellulitis and erysipelas: antimicrobial prescribing (NG141)

    This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.